View:
Download DOC
Download PDF
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Huller Kelly
(Last) (First) (Middle)
VALLEY FORGE BUSINESS CENTER
2560 GENERAL ARMISTEAD AVENUE
(Street)
AUDUBON PA 19403
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
02/27/2019 		3. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, General Counsel
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Stock 15,384 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock) (1) 06/16/2020 Class A Common Stock 3,076 11.86 D
Stock Option (Right to Buy Class A Common Stock) (2) 02/11/2021 Class A Common Stock 23,076 11.28 D
Stock Option (Right to Buy Class A Common Stock) (3) 08/29/2022 Class A Common Stock 2,500 15.34 D
Stock Option (Right to Buy Class A Common Stock) (4) 01/30/2023 Class A Common Stock 7,500 12.59 D
Stock Option (Right to Buy Class A Common Stock) (5) 03/04/2024 Class A Common Stock 7,500 24.9 D
Stock Option (Right to Buy Class A Common Stock) (6) 04/01/2025 Class A Common Stock 7,500 25.8 D
Stock Option (Right to Buy Class A Common Stock) (7) 02/02/2026 Class A Common Stock 7,500 24.21 D
Stock Option (Right to Buy Class A Common Stock) (8) 02/02/2027 Class A Common Stock 7,500 25.96 D
Stock Option (Right to Buy Class A Common Stock) (9) 02/02/2028 Class A Common Stock 10,000 45.64 D
Stock Option (Right to Buy Class A Common Stock) (10) 01/22/2029 Class A Common Stock 40,000 43.58 D
Explanation of Responses:
1. These options were granted on June 16, 2010 and are fully vested.
2. These options were granted on February 11, 2011 and are fully vested.
3. These options were granted on August 29, 2012 and are fully vested.
4. These options were granted on January 30, 2013 and are fully vested.
5. These options were granted on March 4, 2014 and are fully vested.
6. These options were granted on April 1, 2015 and are fully vested.
7. These options were granted on February 2, 2016, and vest over a four-year period with one-fourth(1/4) of the options granted vesting on January 1, 2017, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
8. These options were granted on February 2, 2017, and vest over a four-year period with one-fourth(1/4) of the options granted vesting on January 1, 2018, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
9. These options were granted on February 2, 2018, and vest over a four-year period with one-fourth(1/4) of the options granted vesting on January 1, 2019, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
10. These options were granted on January 22, 2019, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2020, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
Remarks:
/s/ Kelly G. Huller 03/06/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
	Know all by these presents that the undersigned hereby constitutes and appoints
Adam M. Cole, acting alone, signing singly, the undersigned's true and lawful
attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer, director and/or 10% or more stockholder of
Globus Medical, Inc. (the "Company"), Forms ID, 3, 4, 5 and Update Passphrase
Acknowledgement (and any amendments thereto) in accordance with Section 16(a) of
the Securities Exchange Act of 1934, as amended (the "1934 Act"), and the rules
promulgated thereunder; (2) do and perform any and all acts for and on behalf of
the undersigned which may be necessary or desirable to complete and execute any
such Form ID, 3, 4, 5 and Update Passphrase Acknowledgement (and any amendments
thereto) and to file timely such form with the United States Securities and
Exchange Commission and any stock exchange or similar authority; and (3) take
any other action of any type whatsoever in connection with the foregoing which
in the opinion of such attorney-in-fact may be of benefit to, in the best
interest of, or legally required by, the undersigned, it being understood that
the documents executed by such attorney-in-fact on behalf of the undersigned
pursuant to this Power of Attorney shall be in such form and shall contain such
terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

	The undersigned hereby grants to such attorney-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary or
proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the 1934 Act.

	This Power of Attorney revokes any and all prior powers of attorney and shall
remain in full force and effect until the undersigned is no longer required to
file Forms ID, 3, 4 and 5 with respect to the undersigned's holdings of and
transactions in securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorney-in-fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 5 day of March 2019.



/s/ Kelly G. Huller
Kelly G. Huller